R&D
OmniaMed Co., Ltd. opens up a new paradigm for the development of treatments using Nitric Oxide functionality.
Pipeline Overview
| Pipeline | Indication Therapeutic Area |
Development Phase | ||
|---|---|---|---|---|
|
Development
Preclinical
Efficacy CMC
Preclinical
Toxicity Phase 1
|
||||
| Tech 1. | OM-101 | Melanoma metastasis |
|
|
| Tech 2. | OM-201 | Osteoarthritis |
|
|
| Rheumatoid Arthritis |
|
|||
| OM-201 | Colon cancer |
|
||
| Inflammatory bowel diseases |
|
|||
| OM-203 | Inflammation & Cancer |
|
||
| Tech 3. | OM-301 | Glioblastoma |
|
|
| Alzheimer’s Disease |
|
|||
Branch office 13F, Sungeui Bldg., PCBMI, 222, Banpo-daero, Seocho-gu, Seoul 06591 Korea
Tel. 054-279-8137 Fax. 02-2258-7848 Email. omniamed@omnmed.com
(c)2021 OMNIAMED. ALL rights reseved.